To the editor:

Adult Burkitt lymphoma/leukemia (BLL) is a rare, aggressive B-cell neoplasm with typical morphologic appearances. It is characterized by rapid proliferation of mature B cells (Ki67/MIB-1 staining ≥ 99%) and overexpression of c-Myc, which most commonly results from the translocation t(8;14) and less frequently from t(2;8) and t(8;22). Based on shared genetic and molecular features, the World Health Organization (WHO) classification now recognizes a lymphomatous and leukemic phase of this disease as a single entity.1 

Overall improved outcomes with remission rates of 65% to 100% and long-term survival of 40% to 80% have been reported following introduction of intensive multidrug regimens such as CODOX-M/IVAC and Hyper-CVAD.2-4  Furthermore, the addition of rituximab (RTX), a monoclonal anti-CD20 antibody, has further increased responses.5  Recognized prognostic factors in BLL are old age, raised level of lactate dehydrogenase, poor performance status, and advanced stage disease and are used in some protocols to distinguish between low-risk and high-risk disease. Thus adjusting treatment intensity accordingly has proven beneficial.2,4  Nevertheless, the majority of patients with advanced-stage disease achieve durable remissions if treated with these chemotherapy regimens. Recently, Mead et al reported the results of the MRC/NCRI LY10 trial.6  They found a 2-year progression-free survival (PFS) of 64% (95% confidence interval, 51%-77%) following treatment with CODOX-M/IVAC in 58 patients with BLL and did not identify clinical differences relating to the disease sites involved at presentation.

In contrast, we have observed a very poor outcome of adult patients with sporadic BLL and bone marrow involvement. Between 1998 and 2008, 13 patients were diagnosed within the Greater Manchester area in the United Kingdom. All patients were HIV-negative and received treatment with alternating CODOX-M/IVAC as per LY06 or LY10, with or without RTX.4,6  The median age was 42 years (range, 19-69 years). Patients were diagnosed by a specialist hematopathology service according to WHO criteria. Patient characteristics are summarized in Table 1. There were no treatment-related deaths. Four patients had refractory disease and subsequently died of disease progression; 4 patients underwent stem cell transplantation (SCT); patients 1 and 7 had an allogeneic sibling, patient 9 had a matched unrelated donor SCT, and patient 6 had an autologous SCT. All patients relapsed and died within 2 months of completing therapy. The median overall survival from diagnosis was 5 months (range, 4-17 months) and median progression-free survival was 3 months (range, 0-12 months). For those who achieved remission (n = 9), median time from completion of therapy to relapse was less than 1 month (range 0-12).

Table 1

Pretreatment patient characteristics

PatientSexAge, yAnn Arbor stageWHO performance statusLDHPrimary siteBone marrow cytogenetics
30 IV 1531 BM, neck mass 47,XX,der (1)del(1)(p31)add(1)(q42),der(1)del(1)(p12)add(1)(q42),der(2)add(2)(p15),+7,t(8;14)(q24;q32), t(8;14)(q24;q32),t(14;18)(q32;q21),add(17)(p13) 
69 IV NA BM 45-47, X, add(X)(q2?6), del(1)(p13), add(4)(q35), −6, +7, t(8;14)(q24;q32), −10, add(10)(q2?4), del(13) (q12q14), t(14;18)(q32;q21), add(17)(p1?1), ?+21 
24 IV 24600 BM 49,XX,add(9)(p22),del(9)(p22), + mar x 3 [3]/ 46,XX [1] 
50 IV 17000 BM, axillary mass 51XY, der(1)t(1;1)(p36;q?21), +7, add(8)(p?), +12, add(14)(q32), +17, der(18)t(14;18)(q32;q21), +20,+21, der(22)t(8;22)(q24;q11) 
19 IV 2137 BM, parotid mass, CNS 49,XY,+X,dic(1;1)(p11;q4?2),+7,+8,t(8;14)(q24;q32)[7]/50,XY,+X,+del(1)(p2?2),+7,+8,t(8;14)(q24;q32)[4] 
60 IV 1326 BM 47, XY, t(2;8)(p12;q24), add(3)(q2?1), der(6)t(3;6)(q13;q1?3), der(8)t(3;8)(p21;p?21), −9, add(12)(p13), +?del(16)(q22), +18, add(20)(q1?1) 
25 IV 6567 BM 45, X, -X, t(8;9;14)(q24;p13;q32)del(8)(p11)[12]/46, XX[2] 
33 IV 2800 BM 46,XX,t(8;14)(q24;q32),der(13)t(1;13)(q11;q34)[10]/46,XX[1] 
33 IV 20000 BM 46,XY,t(2;8)(p12;q24), t(3;22)(q27;q11), t(14;18)(q32;q21) [1]/46,idem t(6;9)[4]/46,idem t(6;9), der(14), t(14;18)[2]/46,idem der(14), t(14;18)[2]/46,XY[1] 
10 42 IV 27150 BM 46, XY, dic dup(1)(p11q32), t(8;14)(q24;q32)[8]/92, indemx2[2] 
11 66 IV 2309 BM 46, XY, dup1q(q23;q32), t(8;22)(q24;q32), del9q(q12;q22) 
12 66 IV 1953 BM, CNS, abdominal mass 46XY, t(8:14)(q24:q32), del (13) (q14q22)[10] 
13 59 IV 8133 BM 46XY, der (1) t(1:11)(q21;q13), t (2:18)(p12;q21), t(14;18)(q24;q32), −11, del(13)(q12q14), +mar[15]/46, idem, del(6)(q13q21)[3]/46,XY 
PatientSexAge, yAnn Arbor stageWHO performance statusLDHPrimary siteBone marrow cytogenetics
30 IV 1531 BM, neck mass 47,XX,der (1)del(1)(p31)add(1)(q42),der(1)del(1)(p12)add(1)(q42),der(2)add(2)(p15),+7,t(8;14)(q24;q32), t(8;14)(q24;q32),t(14;18)(q32;q21),add(17)(p13) 
69 IV NA BM 45-47, X, add(X)(q2?6), del(1)(p13), add(4)(q35), −6, +7, t(8;14)(q24;q32), −10, add(10)(q2?4), del(13) (q12q14), t(14;18)(q32;q21), add(17)(p1?1), ?+21 
24 IV 24600 BM 49,XX,add(9)(p22),del(9)(p22), + mar x 3 [3]/ 46,XX [1] 
50 IV 17000 BM, axillary mass 51XY, der(1)t(1;1)(p36;q?21), +7, add(8)(p?), +12, add(14)(q32), +17, der(18)t(14;18)(q32;q21), +20,+21, der(22)t(8;22)(q24;q11) 
19 IV 2137 BM, parotid mass, CNS 49,XY,+X,dic(1;1)(p11;q4?2),+7,+8,t(8;14)(q24;q32)[7]/50,XY,+X,+del(1)(p2?2),+7,+8,t(8;14)(q24;q32)[4] 
60 IV 1326 BM 47, XY, t(2;8)(p12;q24), add(3)(q2?1), der(6)t(3;6)(q13;q1?3), der(8)t(3;8)(p21;p?21), −9, add(12)(p13), +?del(16)(q22), +18, add(20)(q1?1) 
25 IV 6567 BM 45, X, -X, t(8;9;14)(q24;p13;q32)del(8)(p11)[12]/46, XX[2] 
33 IV 2800 BM 46,XX,t(8;14)(q24;q32),der(13)t(1;13)(q11;q34)[10]/46,XX[1] 
33 IV 20000 BM 46,XY,t(2;8)(p12;q24), t(3;22)(q27;q11), t(14;18)(q32;q21) [1]/46,idem t(6;9)[4]/46,idem t(6;9), der(14), t(14;18)[2]/46,idem der(14), t(14;18)[2]/46,XY[1] 
10 42 IV 27150 BM 46, XY, dic dup(1)(p11q32), t(8;14)(q24;q32)[8]/92, indemx2[2] 
11 66 IV 2309 BM 46, XY, dup1q(q23;q32), t(8;22)(q24;q32), del9q(q12;q22) 
12 66 IV 1953 BM, CNS, abdominal mass 46XY, t(8:14)(q24:q32), del (13) (q14q22)[10] 
13 59 IV 8133 BM 46XY, der (1) t(1:11)(q21;q13), t (2:18)(p12;q21), t(14;18)(q24;q32), −11, del(13)(q12q14), +mar[15]/46, idem, del(6)(q13q21)[3]/46,XY 

BM indicates bone marrow; and NA, not available.

We believe that bone marrow involvement with complex cytogenetics is most important in determining prognosis in this subgroup of BLL and would like to emphasize this observation. It would therefore be useful for the authors of the recently reported LY10 trial to perform a subgroup analysis for those patients with bone marrow involvement, and assess outcome with respect to their karyotypes. Furthermore, alternative treatment strategies are required for this subgroup of patients, as salvage treatments are rarely, if ever, successful in refractory or relapsed disease.2,7,8  Further trials are needed to re-evaluate the role of SCT as well as other experimental treatments such as radioimmunotherapy (Zevelin) or molecular therapies targeting c-Myc.

Contribution: E.T. analyzed data and wrote the manuscript; S.W. collected data and wrote the manuscript; J.C., H.G., J.B.H., and G.S.L. collected data; J.B. wrote the manuscript; and J.A.L.Y. supervised the study and wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Prof John A. Liu Yin, Consultant Haematologist, Manchester Royal Infirmary, Cobbett House, Oxford Rd, Manchester, M13 9WL, United Kingdom; e-mail: [email protected].

1
Harris
 
NL
Jaffe
 
ES
Diebold
 
J
, et al. 
The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997.
Ann Oncol
1999
, vol. 
10
 
12
(pg. 
1419
-
1432
)
2
Magrath
 
I
Adde
 
M
Shad
 
A
, et al. 
Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen.
J Clin Oncol
1996
, vol. 
14
 
3
(pg. 
925
-
934
)
3
Magrath
 
IT
Janus
 
C
Edwards
 
BK
, et al. 
An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults.
Blood
1984
, vol. 
63
 
5
(pg. 
1102
-
1111
)
4
Mead
 
GM
Sydes
 
MR
Walewski
 
J
, et al. 
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.
Ann Oncol
2002
, vol. 
13
 
8
(pg. 
1264
-
1274
)
5
Thomas
 
DA
Faderl
 
S
O'Brien
 
S
, et al. 
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Cancer
2006
, vol. 
106
 
7
(pg. 
1569
-
1580
)
6
Mead
 
GM
Barrans
 
SL
Qian
 
W
, et al. 
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).
Blood
2008
, vol. 
112
 
6
(pg. 
2248
-
2260
)
7
Sweetenham
 
JW
Pearce
 
R
Taghipour
 
G
Blaise
 
D
Gisselbrecht
 
C
Goldstone
 
AH
Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma–outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation.
J Clin Oncol
1996
, vol. 
14
 
9
(pg. 
2465
-
2472
)
8
Thomas
 
DA
Cortes
 
J
O'Brien
 
S
, et al. 
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
J Clin Oncol
1999
, vol. 
17
 
8
(pg. 
2461
-
2470
)
Sign in via your Institution